Drug Pipeline News

Latest News

Sildenafil cream demonstrates positive phase 2b results for female sexual arousal disorder | Image Credit: © Siam - © Siam - stock.adobe.com.
Sildenafil cream demonstrates positive phase 2b results for female sexual arousal disorder

June 5th 2023

Daré Bioscience has announced positive results from a phase 2b trial analyzing the safety and efficacy of sildenafil cream, 3.6% in women with female sexual arousal disorder.

FDA approves fezolinetant for vasomotor symptoms: © Aquir - stock.adobe.com
FDA approves fezolinetant for vasomotor symptoms

May 12th 2023

FDA advisory panel backs over-the-counter birth control pill | Image Credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com.
FDA advisory panel backs over-the-counter birth control pill

May 10th 2023

Gepotidacin meets endpoints for uUTI studies, eyes potential FDA approval this year
Gepotidacin meets endpoints for uUTI studies, eyes potential FDA approval this year

April 19th 2023

Phase 1 study demonstrates positive results for DARE-HRT1 as VMS treatment | Image Credit: © Production Perig - © Production Perig - stock.adobe.com.
Phase 1 study demonstrates positive results for DARE-HRT1 as VMS treatment

April 18th 2023

Video Interviews
Podcasts
Latest CME Events & Activities

Community Practice Connections™: Translating Recent Evidence on CAR T-Cell Therapy to the Real-World Management of Lymphoid Malignancies

View More

Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future

View More

Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Medical Crossfire®: Experts Address Burning Questions in DLBCL—Sequencing CD19-Targeted Therapies, Strategies Post-CAR T Relapse, Novel Agents, and More!

View More

Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

On-Demand Video Updates from the Annual Oncology Meeting

View More

Expert Illustrations and Commentaries™: Placing New MPN Therapies Into Context Through Illustrated Case Discussions

View More

Advances In™: The Role of NRG1 Fusions Across Tumor Types

View More

Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication

View More

Patient, Provider, and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of TNBC

View More

Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication

View More

How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer

View More

How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer

View More

Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes

View More

Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes

View More

Medical Crossfire®: Evaluating the Potential Role of Next-Generation Selective Estrogen Receptor Degraders in the ER+/HER2- Breast Cancer Treatment Paradigm

View More

Hot Seat™: Expert Considerations to Maximize the Clinical Benefits of Targeted Therapies in Patients With Relapsed/Refractory DLBCL

View More

22nd Annual International Congress on the Future of Breast Cancer® East

View More

22nd Annual International Congress on the Future of Breast Cancer® East

View More

BURST CME™: Exploring the Biologic Rationale for Novel IRAK4-directed Therapy for the Treatment of High Risk MDS and AML

View More

Medical Crossfire®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?

View More

4th Annual International Congress on the Future of Women’s Health™

07/22/2023

View More

Advances In: Interprofessional Strategies to Optimize Outcomes for Patients with Relapsed/Refractory Multiple Myeloma: Expert Discussions to Maximize Safety and Efficacy

View More

Community Practice Connections™: Incorporating Novel Therapies Into Treatment Algorithms Across Acute and Chronic GVHD

View More

Clinical Vignettes™: Testing and Treatment Strategies in Cholangiocarcinoma

View More

22nd Annual International Congress on the Future of Breast Cancer® West

View More

22nd Annual International Congress on the Future of Breast Cancer® West

View More

More News

© 2023 MJH Life Sciences

All rights reserved.